Literature DB >> 10397241

Association of the NAD(P)H:quinone oxidoreductase 609C-->T polymorphism with a decreased lung cancer risk.

H Chen1, A Lum, A Seifried, L R Wilkens, L Le Marchand.   

Abstract

The NAD(P)H:quinone oxidoreductase gene, NQO1, often carries a C-->T transition at bp 609, which has been associated with a reduced enzymatic activity and which may result in altered metabolic activation of tobacco smoke procarcinogens. We tested the association of this polymorphism with lung cancer risk in a population-based case-control study of 327 cases and 440 controls of Caucasian, Japanese, or Native Hawaiian ancestry in Hawaii. We found a notable difference in the frequency of the variant allele among Japanese (38%), Caucasians (20%), and Hawaiians (22%). Overall, the variant allele was less frequent in cases than in controls (P = 0.03). A significant inverse association was found in Japanese, with adjusted odds ratios of 0.8 (95% confidence interval, 0.4-1.5) and 0.3 (0.1-0.7) for the heterozygous and homozygous variant genotypes, respectively, compared with the homozygous wild-type genotype (P for genetic trend, 0.02). The association did not reach statistical significance in Caucasians and Hawaiians but was in the same direction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10397241

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  NQO1 C609T polymorphism associated with esophageal cancer and gastric cardiac carcinoma in North China.

Authors:  Jian-Hui Zhang; Yan Li; Rui Wang; Helen Geddert; Wei Guo; Deng-Gui Wen; Zhi-Feng Chen; Li-Zhen Wei; Gang Kuang; Ming He; Li-Wei Zhang; Ming-Li Wu; Shi-Jie Wang
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

2.  E3 ligase STUB1/CHIP regulates NAD(P)H:quinone oxidoreductase 1 (NQO1) accumulation in aged brain, a process impaired in certain Alzheimer disease patients.

Authors:  Peter Tsvetkov; Yaarit Adamovich; Evan Elliott; Yosef Shaul
Journal:  J Biol Chem       Date:  2011-01-10       Impact factor: 5.157

Review 3.  Association between NQO1 C609T polymorphism and prostate cancer risk.

Authors:  Zihan Sun; Yuling Cui; Jing Pei; Zhiqiang Fan
Journal:  Tumour Biol       Date:  2014-05-17

Review 4.  Colorectal cancer: a researcher's perspective of the molecular angel's gone eccentric in the Vale of Kashmir.

Authors:  Aga Syed Sameer
Journal:  Tumour Biol       Date:  2013-02-17

Review 5.  Association between NQO1 C609T polymorphism and acute lymphoblastic leukemia risk: evidence from an updated meta-analysis based on 17 case-control studies.

Authors:  Cuiping Li; Yang Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-02       Impact factor: 4.553

Review 6.  Genetic susceptibility to lung cancer--light at the end of the tunnel?

Authors:  Ariela L Marshall; David C Christiani
Journal:  Carcinogenesis       Date:  2013-01-24       Impact factor: 4.944

7.  Amide linked redox-active naphthoquinones for the treatment of mitochondrial dysfunction.

Authors:  Krystel L Woolley; Monila Nadikudi; Mitra N Koupaei; Monika Corban; Paul McCartney; Alex C Bissember; Trevor W Lewis; Nuri Gueven; Jason A Smith
Journal:  Medchemcomm       Date:  2019-01-16       Impact factor: 3.597

8.  NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: a meta-analysis.

Authors:  Yuqing Lou; Rong Li; Liwen Xiong; Aiqin Gu; Chunlei Shi; Tianqing Chu; Xueyan Zhang; Ping Gu; Hua Zhong; Shaojun Wen; Baohui Han
Journal:  Tumour Biol       Date:  2013-07-14

9.  Lack of association between NADPH quinone oxidoreductase 1 (NQO1) gene C609T polymorphism and lung cancer: a case-control study and a meta-analysis.

Authors:  Shujie Guo; Min Gao; Xiaobo Li; Yuqiong Li; Shaoli Chu; Dingliang Zhu; Wenquan Niu
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

10.  Colorectal cancer: molecular mutations and polymorphisms.

Authors:  Aga Syed Sameer
Journal:  Front Oncol       Date:  2013-05-13       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.